Reata has two important partners in developing our lead product, bardoxolone methyl, outside the United States. Kyowa Hakko Kirin, Tokyo, JP, has licensed rights to develop the product in Japan and other select Asian Territories. Abbott Laboratories is codeveloping bardoxolone methyl globally with Reata and will commercialize the product in other global territories outside the US and Asia. Reata will independently launch and commercialize bardoxolone methyl in the United States.

January 7, 2010: Reata Pharmaceuticals Licenses CKD Drug to Kyowa Hakko Kirin for Asian Markets

September 23, 2010: Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.

December 12, 2011: Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modulators